UPDATE: Credit Suisse Upgrades Ironwood Pharmaceuticals to Outperform on Positive Linzess Survey
Credit Suisse upgraded Ironwood Pharmaceuticals (NASDAQ: IRWD) from Neutral to Outperform and raised the price target from $15.00 to $24.00.
Credit Suisse analyst Catherine Arnold commented, "CS proprietary market research survey with ~100 physicians implies greater demand via both category expansion and competitive market share. Respondents include 55% gastroenterologists and 45% PCPs, ~70% who were early Linzess users, and all with brand awareness."
Ironwood Pharmaceuticals closed at $17.68 on Thursday.
Latest Ratings for IRWD
|Feb 2015||JP Morgan||Maintains||Overweight|
|Feb 2015||Cantor Fitzgerald||Upgrades||Sell||Hold|
|Dec 2014||JP Morgan||Maintains||Overweight|
© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.